Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 19/20 | 0.73 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.59 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8673151 | 0.95 | ESR1 (0.79) | ESR1ESR2ENPP3ENPP1 | |
| SCHEMBL8671067 | 0.92 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL4822091 | 0.89 | ESR1 (0.67) | ESR1ESR2ENPP3ENPP1 | |
| SCHEMBL8598366 | 0.86 | ESR1 (0.89) | ESR1ESR2ENPP3ENPP1 | |
| SCHEMBL8598353 | 0.86 | ESR1 (0.89) | ESR1ESR2ENPP3ENPP1 | |
| SCHEMBL8600306 | 0.85 | ESR1 (0.88) | ESR1ESR2ENPP3ENPP1 | |
| SCHEMBL8676838 | 0.85 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL7817127 | 0.84 | CNR2 (0.61) | ESR1ESR2 | |
| SCHEMBL11554399 | 0.84 | ESR1 (0.88) | ESR1ESR2ENPP3ENPP1 | |
| SCHEMBL8599297 | 0.83 | ESR1 (0.80) | ESR1ESR2ENPP3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119206-B2 | Derivative of dihydro-dibenzo (a) anthracenes and their use as selective estrogen receptor modulators | ELI LILLY AND COMPANY (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060122386-A1 | Derivative of dihydro-dibenzo (a) anthracenes and their use as selective estrogen receptor modulators | ELI LILLY AND COMPANY | 2006-06-08 | — | — | US | disclosed |
| EP-1546139-A1 | DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029047-A1 | DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122386-A1 | Derivative of dihydro-dibenzo (a) anthracenes and their use as selective estrogen receptor modulators | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885ENPP3 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.